Abstract
AbstractTransfeminine adults are impacted by the HIV epidemic in the Philippines, and newly approved modalities of pre-exposure prophylaxis (PrEP), including long-acting injectable (LAI-PrEP), could be beneficial for this group. We utilized secondary data from the #ParaSaAtin survey that sampled Filipina transfeminine adults (n=139) and conducted a series of multivariable logistic regressions with lasso selection to explore factors independently associated with PrEP outcomes, including awareness, discussion with trans friends, and interest in LAI-PrEP. Overall, 53% of Filipina transfeminine respondents were aware of PrEP, 39% had discussed PrEP with their trans friends, and 73% were interested in LAI-PrEP. PrEP awareness was associated with being non-Catholic, having previously been HIV tested, discussing HIV services with a provider, and having high HIV knowledge (p<0.05). Discussing PrEP with friends was associated with older age, having experienced healthcare discrimination due to transgender identity, having HIV tested, and having discussed HIV services with a provider (p<0.05). Interest in LAI-PrEP was associated with living in Central Visayas, having discussed HIV services with a provider, and having discussed HIV services with a sexual partner were associated (p<0.05). Implementing LAI-PrEP in the Philippines requires addressing systemic improvements across personal, interpersonal, social, and structural levels in healthcare access, including efforts to create healthcare settings and environments with providers who are trained and competent in transgender health and can address the social and structural drivers of trans health inequities, including HIV and barriers to LAI-PrEP.
Publisher
Cold Spring Harbor Laboratory
Reference53 articles.
1. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2021. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS Available at: https://www.unaidsorg/sites/default/files/media_asset/2020_aids-data-book_enpdf. 2021.
2. PrEPWatch A. Country Updates: Philippines 2022.
3. Health Technology Assessment Council - Philippines Department of Health. Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection. Available at: https://bit.ly/HTAC-ES-OralPrEP_Recomm. 2022.
4. Joint United Nations Programme on HIV/AIDS [UNAIDS]. UNAIDS Data 2019 2020.
5. Cabotegravir for HIV prevention in cisgender men and transgender women;New England Journal of Medicine,2021